Stock ALXO ALX ONCOLOGY HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-07 pm EDT 		5-day change 1st Jan Change
17.56 USD +11.28% Intraday chart for ALX Oncology Holdings Inc. +3.17% +17.93%
May. 07 ALX Oncology Appoints Allison Dillon as Chief Business Officer CI
Apr. 30 ALX Oncology Holdings Inc. Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ALX Oncology Appoints Allison Dillon as Chief Business Officer
GL
ALX Oncology Appoints Allison Dillon as Chief Business Officer
AQ
ALX Oncology Appoints Allison Dillon as Chief Business Officer
CI
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
GL
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
AQ
ALX Oncology Holdings Inc. Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
CI
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
GL
Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing
MT
ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept
MT
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
GL
ALX Oncology Holdings Inc. Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (?R/R B-NHL?)
CI
UBS Adjusts ALX Oncology Price Target to $25 From $27, Maintains Buy Rating
MT
ALX Oncology : Corporate Presentation
PU
H.C. Wainwright Adjusts Price Target on ALX Oncology to $20 From $17.50, Keeps Buy Rating
MT
North American Morning Briefing : Stock Futures -2-
DJ
Piper Sandler Adjusts Price Target on ALX Oncology Holdings to $21 From $11, Maintains Overweight Rating
MT
Stifel Downgrades ALX Oncology Holdings to Hold From Buy, Adjusts Price Target to $14 From $10
MT
ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALXO Stock
  4. News ALX Oncology Holdings Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW